سعر فيبيوريك 120 مجم 10 قرص 2024

Febuxostat 120 mg film-coated tablets (Hikma Pharma), 1 strip x 10 film-coated tablets per pack.

• Treatment of chronic hyperuricaemia in conditions where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis) in adults.Population: AdultsEuropean Medicines Agency (EMA)
• Prevention and treatment of hyperuricaemia in adult patients undergoing chemotherapy for haematologic malignancies at intermediate to high risk of tumor lysis syndrome (TLS) (120 mg strength).Population: AdultsEuropean Medicines Agency (EMA)

• EU most commonly reported: gout flares, liver function abnormalities, diarrhoea, nausea, headache, dizziness, dyspnoea, rash, pruritus, arthralgia, myalgia, pain in extremity, oedema and fatigue; rare serious hypersensitivity reactions and sudden cardiac death post-marketing.International label, equivalent formulation · European Medicines Agency (EMA)

• EU: hypersensitivity to febuxostat or any excipient.International label, equivalent formulation · European Medicines Agency (EMA)

• EU: in patients with pre-existing major cardiovascular disease more fatal CV events were seen versus allopurinol in CARES (not confirmed in FAST); treat cautiously with regular monitoring. Serious hypersensitivity reactions (SJS, TEN, anaphylaxis, DRESS) mostly in the first month: stop immediately and never restart. Not recommended with mercaptopurine/azathioprine, in organ transplant recipients or where urate formation is greatly increased (xanthine deposition). Liver function tests before and periodically during treatment; caution with thyroid dysfunction (TSH increases); contains lactose.International label, equivalent formulation · European Medicines Agency (EMA)

• Mercaptopurine/azathioprineEU: not recommended (xanthine oxidase inhibition raises their levels, risk of myelotoxicity); if unavoidable reduce their dose to 20% or less of the previous dose with close monitoring.European Medicines Agency (EMA)
• TheophyllineEU: febuxostat 80 mg with theophylline showed no pharmacokinetic interaction; no data are available for febuxostat 120 mg.European Medicines Agency (EMA)

• EU: very limited pregnancy data without adverse effects; animal studies show no harm; potential human risk unknown; febuxostat should not be used during pregnancy.International label, equivalent formulation · European Medicines Agency (EMA)
• EU: unknown whether excreted in human milk; excreted in animal milk with impaired pup development; should not be used while breastfeeding.International label, equivalent formulation · European Medicines Agency (EMA)

• Febuxostat: Potent non-purine selective inhibitor of xanthine oxidase, reducing serum uric acid.